ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKER01

Structure-guiding tools to study the role of choline in the development of congenital hydrocephalus

Active
Institution
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA
Principal investigator
Thomas Darmody Arnold
Funding
$655K
Duration
2025–2030
Open portfolio

Moonbase score

Still being scored

Abstract

PROJECT SUMMARY The blood-brain barrier (BBB) is a term used to describe the unique properties of the blood vessels that vascularize the central nervous system (CNS) and restrict the movement of nutrients, ions and cells between the blood and the brain. BBB dysfunction contributes to various CNS diseases and greatly impedes drug delivery. Despite its importance, little progress has been made in manipulating the BBB due to a major gap in our understanding, and a lack of tools to interrogate, constituents of the BBB at a molecular and cellular level. We have found that mutations in the blood brain barrier (BBB) choline transporter, FLVCR2, or the related choline and ethanolamine transporter, FLVCR1 (expressed in brain neuroprogenitor cells, NPCs), cause congenital hydrocephalus (CH). However, the mechanisms by which FLVCR1 and FLVCR2 transport choline and contribute to the development of CH are unknown, and we currently lack the tools to probe these mechanisms at a molecular level. In this proposal we will address this void through three specific Aims: In Aim 1, we will determine the structures of FLVCR1 and FLVCR2 using cryo-electron microscopy (cryoEM), so as to provide a model to generate structure-based functional hypotheses. In Aim 2, using radioactive and fluorescently tagged choline tracers and innovative heme reporters, combined cell-culture techniques, we will define the mechanisms of choline transport and heme-choline interactions in brain endothelial cells and NPCs, and test structure-based hypotheses in vitro. In Aim 3, we will utilize CRISPR/CAS9 to generate a series of new mouse models of CH bearing conditional mutation in FLVCR1 or FLVCR2 to test structure:function relationships in vivo. These new tools will be freely disseminated to the scientific community and should have a catalytic effect on the field. Our preliminary data include cryoEM analysis of recombinant FLVCR2 and complex formation with FLVCR1/2-cross reactive antibodies (Fabs); the generation of CRISPR/CAS9-mediated Flvcr2 knockout brain endothelial cells, Flvcr1 knockout HEK293 cells, and a NPC culture platform; the generation of FLVCR2 brain endothelial cell specific conditional knockout/knockin and FLVCR1 NPC specific conditional knockout mouse models of CH. These data demonstrate that we are well-poised for structural determination and the development of an adaptable cell-based assays and genetic mouse models for future structure/function studies on FLVCR1 and FLVCR2, and their collaborative roles in BBB choline transport and CH.

LOADING MOONBASE SCORE

R01NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKESpecial Emphasis Panel[ZRG1 BN-M (91)]cryoemhydrocephaluslack toolscholinebbbstructure-basednpcsnpc

Questions for UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

Answered by the team behind this research.

Same researchers, same institution, same topic, scored first.